| NASDAQ (usa) | 
    	      | 
    6715.56 | -12.11 | -0.18% | 
| FTSE 100 (london) | 
	![]()  | 
    7487.96 | -5.12 | -0.07% | 
| DAX (german) | 
	      | 
    13465.51 | 235.94 | 1.78% | 
| NIKKEI 225 (japan) | 
	      | 
    22420.08 | 408.47 | 1.86% | 
| Hang - Seng (hong kong) | 
	      | 
    28594.06 | 348.52 | 1.23% | 
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) | 
	      | 
    3391.61 | 17.53 | 0.52% | 
| KOSPI (korea) | 
	      | 
    2556.47 | 33.04 | 1.31% | 
| All Ordinaries (australia) | 
	      | 
    6005.30 | 28.90 | 0.48% | 
| BOVESPA (brazil) | 
	      | 
    74092.76 | -215.73 | -0.29% | 
Phio Pharmaceuticals Corp (NASDAQ: PHIO)
                                    	PHIO Technical Analysis
                                    
                                    
    3
    
    
    
    
									| As on 3rd Nov 2025 PHIO STOCK Price closed @ 1.86 and we RECOMMEND Sell for LONG-TERM with Stoploss of 2.32 & Sell for SHORT-TERM with Stoploss of 2.04 we also expect STOCK to react on Following IMPORTANT LEVELS. | 
PHIOSTOCK Price
| Open | 3.46 | Change | Price | % | 
| High | 4.19 | 1 Day | -0.19 | -9.27 | 
| Low | 1.72 | 1 Week | -0.28 | -13.08 | 
| Close | 1.86 | 1 Month | -0.38 | -16.96 | 
| Volume | 161174398 | 1 Year | 1.13 | 154.79 | 
| 52 Week High 6.60 | 52 Week Low 0.58 | ||||
    NASDAQ USA Most Active Stocks
                    | AMRS | 0.14 | 100.00% | 
| WBA | 11.98 | 0.50% | 
| EZGO | 0.18 | 28.57% | 
| NVDA | 206.88 | 2.17% | 
| PHIO | 1.86 | -9.27% | 
| BYND | 1.39 | -16.27% | 
| CIFR | 22.76 | 22.04% | 
| LMDX | 0.02 | 0.00% | 
| BITF | 4.11 | 3.53% | 
| ONDS | 6.15 | -4.50% | 
NASDAQ USA Top Gainers Stocks
                    
                NASDAQ USA Top Losers Stocks
                    
                | PHIO Daily Charts  | 
                PHIO Intraday Charts  | 
                Whats New @  Bazaartrend  | 
                PHIO Free Analysis  | 
              
| 
                
                 | 
              
PHIO Important Levels Intraday
                                    | RESISTANCE | 6.62 | 
| RESISTANCE | 5.09 | 
| RESISTANCE | 4.15 | 
| RESISTANCE | 3.21 | 
| SUPPORT | 0.51 | 
| SUPPORT | -0.43 | 
| SUPPORT | -1.37 | 
| SUPPORT | -2.90 | 
PHIO Forecast  November 2025
                                    | 4th UP Forecast | 2.23 | 
| 3rd UP Forecast | 2.11 | 
| 2nd UP Forecast | 2.04 | 
| 1st UP Forecast | 1.96 | 
| 1st DOWN Forecast | 1.76 | 
| 2nd DOWN Forecast | 1.68 | 
| 3rd DOWN Forecast | 1.61 | 
| 4th DOWN Forecast | 1.49 | 
     PHIO Weekly Forecast
                                    
                                    
                                | 4th UP Forecast | 2.07 | 
| 3rd UP Forecast | 2.00 | 
| 2nd UP Forecast | 1.96 | 
| 1st UP Forecast | 1.92 | 
| 1st DOWN Forecast | 1.80 | 
| 2nd DOWN Forecast | 1.76 | 
| 3rd DOWN Forecast | 1.72 | 
| 4th DOWN Forecast | 1.65 | 
PHIO Forecast2025
                                    | 4th UP Forecast | 19.63 | 
| 3rd UP Forecast | 13.93 | 
| 2nd UP Forecast | 10.41 | 
| 1st UP Forecast | 6.88 | 
| 1st DOWN Forecast | -3.16 | 
| 2nd DOWN Forecast | -6.69 | 
| 3rd DOWN Forecast | -10.21 | 
| 4th DOWN Forecast | -15.91 | 
                                        Phio Pharmaceuticals Corp ( NASDAQ USA Symbol : PHIO ) 
Sector : Healthcare And Other Stocks in Same Sector
                                    
                                    
                                Sector : Healthcare And Other Stocks in Same Sector
PHIO Other Details
                    | Segment | EQ | |
| Market Capital | 22331760.00 | |
| Sector | Healthcare | |
| Industry | Biotechnology | |
| Offical website | > echo $website ; ?> | |
PHIO Address
                                 
                                         ![]()  | 
                                          ||
                                        PHIO Latest News
                                    
                                    
                                    PHIO Business Profile
   
	 Phio Pharmaceuticals Corp., a biotechnology company, develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on silencing tumor-induced suppression of the immune system. The company develops PH-762 which targets the checkpoint protein PD-1 on immune cells for used in adoptive cell transfer (ACT); PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for used in ACT; and PH-790 which targets PD-L1 protein that keeps immune cells from attacking nonharmful cells in the body. It has collaborations with the Gustave Roussy and Medigene AG, as well as with Helmholtz Zentrum München. Phio Pharmaceuticals has collaboration with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts. Address: 257 Simarano Drive, Marlborough, MA, United States, 01752 
	
            
            © 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
 
	   Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service

    
    